Hepatitis D medical therapy: Difference between revisions
No edit summary |
No edit summary |
||
Line 3: | Line 3: | ||
{{CMG}}; {{AOEIC}} {{VK}} | {{CMG}}; {{AOEIC}} {{VK}} | ||
==Medical Therapy== | ==Medical Therapy== | ||
Line 16: | Line 15: | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Infectious disease]] | [[Category:Infectious disease]] | ||
[[Category:Needs overview]] | |||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} |
Revision as of 17:34, 4 December 2012
Hepatitis D |
Diagnosis |
Treatment |
Hepatitis D medical therapy On the Web |
American Roentgen Ray Society Images of Hepatitis D medical therapy |
Risk calculators and risk factors for Hepatitis D medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Varun Kumar, M.B.B.S. [2]
Medical Therapy
There is no specific available treatment. For persons with severe hepatitis, only supportive care is given. The treatment of chronic active hepatitis B and coexistent hepatitis D infection with alpha interferon would be done only after consultation and referral to a gastroenterologist.[1] Monitoring HDV RNA and serological levels of HBsAg may help in management of these patients.[2]
Follow-up for 6months may be recommended in these patients to evaluate for the development of chronic HBV and HDV infection.
References
- ↑ Center for Substance Abuse Treatment. Screening for Infectious Diseases Among Substance Abusers. Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 1993. (Treatment Improvement Protocol (TIP) Series, No. 6.) Chapter 15 - Viral Hepatitis D.
- ↑ Manesis EK, Schina M, Le Gal F, Agelopoulou O, Papaioannou C, Kalligeros C, Arseniou V, Manolakopoulos S, Hadziyannis ES, Gault E, Koskinas J, Papatheodoridis G, Archimandritis AJ (2007). "Quantitative analysis of hepatitis D virus RNA and hepatitis B surface antigen serum levels in chronic delta hepatitis improves treatment monitoring". Antiviral Therapy. 12 (3): 381–8. PMID 17591028.
|access-date=
requires|url=
(help)